nav-left cat-right
cat-right

Point-of-Care Diagnostics Conference June 11-12, 2...

GTCbio invite you to attend the Point-of-Care Diagnostics Conference, which will take place on June 11-12, 2015 in San Diego, CA at the Hyatt Regency Mission Bay. The development of accurate POC testing and its impact on new disease areas and disease management presents many challenges for healthcare providers and manufacturers. Regulatory aspects, validation, clinical applications must be considered when discussing the...

Epigenomics & Novel Therapeutic Targets Confe...

On behalf of GTCbio and the 2015 Advisory Board, you are invited the Epigenomics & Novel Therapeutic Targets Conference which takes place May 21-22, 2015 in Boston, MA. This meeting is part of The Pan-Omics Summit and focuses on transcriptional regulation, novel therapeutic targets and discoveries, pre-clinical to clinical drug development, new technological advances, and epigenomic biomarkers and diagnostics. Epigenomics...

Controlled Release Conference, 20th – 21st A...

As controlled release drug delivery systems continue to play an important role among the emerging areas of research in the treatment of diseases, this event will focus on specific topics looking at advances made in the field and how to overcome the challenges involved when developing controlled release formulations. Returning for its twelfth year and following on from the major success of previous events, SMi are proud to...

Possible treatment for kidney disease in lupus

In the U.S. alone, more than 1.5 million people have lupus, a chronic autoimmune disease in which the immune system turns against itself, attacking a person’s healthy tissue, cells and organs. The symptoms can range from debilitating pain and fatigue to organ failure. Dr. Chandra Mohan, a biomedical engineer at the University of Houston (UH), has a theory about the development of lupus nephritis and, if he’s...

B-cells aggravate autoimmune diseases

Scientists in Freiburg may have discovered a fundamental aggravating factor in autoimmune diseases. If B-lymphocytes lack the protein PTP1B, the cells will become hyperactive for stimulatory signals and can thus promote an autoimmune attack. This study offers an additional explanation to how B-cells regulate an immune response. In Germany, approximately 800,000 people suffer from rheumatoid arthritis. In this progressive...

UK “breakthrough” drug program

Impressed by the success of the FDA’s breakthrough therapy designation, U.K. regulators are considering a similar effort to speed the path for promising drugs, according to an industry group. The nation’s government is in the midst of “active discussion across Whitehall” on a plan that would fast-track certain treatments, according to the trade group U.K. BioIndustry Association. Under the proposal,...
Page 1 of 212